EUVIMEDEUVIMED entdecken
Crossref

Induction treatment for lupus nephritis at a high-complexity hospital in Chile

Paulina Ramirez, Andres Giglio iD, Jorge Verdugo, Francisco Gutierrez

Lupus · 2024

DOI: 10.1177/09612033241249574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lupus, 2024. Verfasst von Paulina Ramirez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Unit, Complejo Asistencial Dr Sótero del Río, Puente Alto, Chile. Hauptthemen laut MEDLINE: Lupus Nephritis, Cyclophosphamide, Immunosuppressive Agents, Mycophenolic Acid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Systemic lupus erythematosus (SLE) causes kidney compromise in up to 40% of patients, contributing significantly to morbidity. Lupus nephritis (LN), an early onset manifestation in most patients, is histologically classified into six types, with types III, IV, and V requiring treatment with induction therapies, usually glucocorticoids with mycophenolate mofetil (MMF) or intravenous cyclophosphamide (IVC). However, up to 60% of patients fail to achieve complete remission, and 27%–66% have subsequent flares. There is scarce literature on the superiority of IVC or MMF in the Latin population. Methodology A retrospective cohort study of 72 LN patients at a high-complexity hospital in Chile between 2016 and 2021 was conducted. Demographics, urine studies, creatinine levels, complement levels, antibody profiles, biopsy results, and response to treatment were analysed.

Results

The median age of the cohort was 29 years, with women representing 90% of patients. At diagnosis, 87.5% of the patients presented with proteinuria, 55% had haematuria, and 49% had acute kidney injury. The most common LN type was type IV. For induction therapy, half of the patients were treated with IVC, and the other half with MMF. The response to treatment did not differ significantly between the two.

Discussion

This is one of the few studies to focus on the Latin American population, specifically Chile. These results are consistent with the current understanding of LN treatment. Despite its limitations, this study provides valuable insights into the treatment effectiveness of IVC and MMF in this population.

Conclusion

This study did not find significant differences in the clinical response to IVC or MMF at 6 months. Future prospective studies are required to determine the optimal induction therapy for LN, especially in Latin populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisCyclophosphamideImmunosuppressive AgentsMycophenolic AcidGlucocorticoidsHumansChileFemaleAdultRetrospective StudiesMaleYoung AdultMiddle AgedTreatment OutcomeRemission InductionAdolescent

Stichwörter der Autor:innen

Latin AmericaNephritisepidemiologylupus nephritisrenal lupussystemic lupus erythematosus

Substanzen

CyclophosphamideImmunosuppressive AgentsMycophenolic AcidGlucocorticoids

Autor:innen und Institutionen

  • Rheumatology Unit, Complejo Asistencial Dr Sótero del Río, Puente Alto, Chile.
  • Internal Medicine Department, Complejo Asistencial, Dr Sótero del Río, Puente Alto, Chile.
  • Critical Care Department, Finis Terrae University, Santiago, Chile.
  • Critical Care Department, Clínica Las Condes Hospital, Las Condes, Chile.

ORCID-Profile: Andres Giglio

Zitieren

APA

Ramirez, P., Giglio, A., Verdugo, J., & Gutierrez, F. (2024). Induction treatment for lupus nephritis at a high-complexity hospital in Chile. Lupus. https://doi.org/10.1177/09612033241249574

Vancouver

Ramirez P, Giglio A, Verdugo J, Gutierrez F. Induction treatment for lupus nephritis at a high-complexity hospital in Chile. Lupus. 2024. doi:10.1177/09612033241249574

BibTeX
@article{Ramirez2024,
  author = {Ramirez, Paulina and Giglio, Andres and Verdugo, Jorge and Gutierrez, Francisco},
  title = {Induction treatment for lupus nephritis at a high-complexity hospital in Chile},
  journal = {Lupus},
  year = {2024},
  doi = {10.1177/09612033241249574}
}
Kostenlos starten →